TO THE EDITOR-An optimal T-cell response against Mycobacterium tuberculosis depends on the balance between costimulatory and coinhibitory signals. In recent years, several studies revealed that, during chronic infection, microorganisms exploit these pathways in their own favor to establish an infection. By inducing overexpression of programmed death 1 (PD-1) and its ligands (PD-L1 and PD-L2) on various immune cells, M. tuberculosis effectively suppresses the T-helper type 1 (Th1) immune response. Recently, we [1, 2] and others [3] [4] [5] demonstrated that M. tuberculosis inhibits T-cell, natural killer cell, and natural killer T-cell effector functions (ie, cytokine release, proliferation, apoptosis, and cytotoxic T-lymphocyte activity) by exploiting the PD-1-PD-L1/PD-L2 pathways.
In Therefore, both studies demonstrate that the PD-1-PD-L1 pathway is involved in dampening the IFN-γ response during tuberculosis and that blocking this pathway provides a rationale to target the pathway for immune restoration. Their results differ from ours in the following respects: (1) there was a marginal increase in PD-L1 expression on CD4 + T cells, and (2) there was a lack of modulation in the frequency and quantity of IFN-γ expression following blockade of PDL-1. The differences possibly stem from the marked difference in their experimental conditions. They followed a sophisticated but completely in vitro approach, whereas we performed our experiments with cells isolated from a near-natural milieu of peripheral blood mononuclear cells from patients with pulmonary tuberculosis. This may underlie the divergences in the results. When signaling through CD28 is delivered at the same time as PD-1 and T-cell receptor (TCR) ligation, inhibitory effects can be overcome, and cytokine production and cell survival is enhanced [7, 8] . Therefore, any strong stimulation can neutralize the inhibitory effect of PD-1 signaling. Since Stephen-Victor et al provided strong polyclonal stimulation (initially through the TCR and then with PMA plus ionomycin), it is quite possible that the effect of the PD-1 blockade was masked and that the M. tuberculosis-specific readout was diluted by the polyclonal nature of their stimulation. Such a high percentage of IFN-γ + cells are usually not observed with any antigen-specific assay system. We performed >50 PD-1-PD-L1 blocking experiments but never observed such high levels of IFN-γ-producing CD4 + T cells. Therefore, the divergence of their results from our observations involving patients with pulmonary tuberculosis may be due to their experimental approach and use of sorted T cells from healthy donors in an in vitro setting. We should be cautious in interpreting and comparing data obtained from such different systems.
We are thankful to Stephan-Victor et el for their comments about our methods of capturing intracellular cytokines with brefeldin A for flow cytometry-based assays. We understand their concerns and would like to clarify that we did not perform blocking experiments by exposing the cells to brefeldin A for 48 hours or 72 hours. We cultured the cells for 48 hours or 72 hours, but brefeldin A was present only during the last 12 hours. We also excluded dead cells from our analysis by use of ethidium monoazide bromide staining, which is capable of excluding dead cells during intracellular cytokine staining and analysis. Recently, we reported our methods with more clarity [2] . We regret the lack of this clarity in our earlier article [1] . Thus, the error they pointed out is not applicable to our current study.
Overall, both studies highlight the critical role of the PD-1-PD-L1 pathway in host immunosuppression during tuberculosis.
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